|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:approves
|
gptkb:2004
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Vesicare
gptkb:solifenacin_succinate
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
|
|
gptkbp:contraindication
|
gptkb:sneaker
gptkb:Insurance_Company
urinary retention
|
|
gptkbp:current_use
|
urge incontinence
bladder dysfunction
neurogenic bladder
|
|
gptkbp:dosage_form
|
once daily
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:tablet
|
|
gptkbp:has_ability
|
10 mg
5 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vesicare
|
|
gptkbp:ingredients
|
gptkb:solifenacin
|
|
gptkbp:interacts_with
|
gptkb:ketoconazole
gptkb:digoxin
gptkb:rifampin
|
|
gptkbp:invention
|
gptkb:2023
|
|
gptkbp:is_available_on
|
generic version
|
|
gptkbp:is_used_for
|
overactive bladder
|
|
gptkbp:lifespan
|
45 to 68 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Astellas_Pharma
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:scholarships
|
avoid alcohol
not recommended for children
consult doctor if pregnant
report severe side effects
may cause drowsiness
|
|
gptkbp:side_effect
|
dizziness
constipation
dry mouth
blurred vision
urinary retention
|
|
gptkbp:bfsParent
|
gptkb:Valeant_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
6
|